PCV43 COST-EFFECTIVENESS ANALYSIS OF RIVAROXABAN VERSUS DABIGATRAN AND ENOXAPARIN FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM AFTER TOTAL HIP REPLACEMENT

May 1, 2011, 00:00
10.1016/j.jval.2011.02.230
https://www.valueinhealthjournal.com/article/S1098-3015(11)00369-X/fulltext
Title : PCV43 COST-EFFECTIVENESS ANALYSIS OF RIVAROXABAN VERSUS DABIGATRAN AND ENOXAPARIN FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM AFTER TOTAL HIP REPLACEMENT
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(11)00369-X&doi=10.1016/j.jval.2011.02.230
First page : A40
Section Title : Disease-Specific Studies
Open access? : No
Section Order : 782
Categories :
Tags :
Regions :
ViH Article Tags :